The Bosentan Patient Registry: long-term survival in pulmonary arterial hypertension
- PMID: 20002851
- DOI: 10.1111/j.1445-5994.2009.02139.x
The Bosentan Patient Registry: long-term survival in pulmonary arterial hypertension
Abstract
Background/aims: The Bosentan Patient Registry (BPR) was a prospective, multicentre, Australian registry funded by Actelion Pharmaceuticals. The primary aim of the registry was to collect survival data in patients with pulmonary arterial hypertension (PAH) treated with bosentan.
Methods: The BPR was initiated in 15 specialized PAH centres. All patients on or starting bosentan were invited to enrol. Treating physicians notified the registry if patients discontinued bosentan, because of either a change in therapy, transplantation, intervention or death. Survival data were validated against the Australian Institute of Health and Welfare National Death Index.
Results: Between 2004 and 2007, a total of 528 patients (mean age 59 ± 17 years) were enrolled representing 69% of patients either previously taking or initiated on bosentan during that time. The BPR population was generally older with more advanced functional deficit than patients enrolled in randomized, placebo-controlled trials. Aetiology was idiopathic (iPAH) in 58% and connective tissue disease related (scleroderma (SSc)-PAH) in 42%. For iPAH patients, World Health Organisation functional classes II, III and IV at enrolment was 8.2%, 66.4% and 20.5%, and for the SSc-PAH cohort, 3.2%, 75.8% and 17.9% respectively. The observed annual mortality was 11.8% in patients with iPAH and 16.6% in patients SSc-PAH.
Conclusion: This large Australian registry provides 'real life' information on the characteristics and management of PAH in clinical practice. Treatment with bosentan improved survival outcomes in both iPAH and SSc-PAH compared with historical controls. Age, disease severity and aetiology were critical factors in determining clinical outcomes.
© 2011 The Authors. Internal Medicine Journal © 2011 Royal Australasian College of Physicians.
Similar articles
-
Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.Eur J Clin Invest. 2006 Sep;36 Suppl 3:10-5. doi: 10.1111/j.1365-2362.2006.01688.x. Eur J Clin Invest. 2006. PMID: 16919005 Clinical Trial.
-
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.Rheumatology (Oxford). 2010 Mar;49(3):490-500. doi: 10.1093/rheumatology/kep398. Epub 2009 Dec 16. Rheumatology (Oxford). 2010. PMID: 20015974 Clinical Trial.
-
Funding linked to ongoing research: impact of the bosentan patient registry on pricing in Australia.Value Health. 2011 Sep-Oct;14(6):961-3. doi: 10.1016/j.jval.2011.02.1177. Value Health. 2011. PMID: 21914519
-
Bosentan.Expert Opin Pharmacother. 2010 Apr;11(6):1023-34. doi: 10.1517/14656561003691854. Expert Opin Pharmacother. 2010. PMID: 20307226 Review.
-
Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension.Am J Cardiovasc Drugs. 2009;9(5):331-50. doi: 10.2165/11202270-000000000-00000. Am J Cardiovasc Drugs. 2009. PMID: 19791841 Review.
Cited by
-
Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews.BMC Health Serv Res. 2013 Mar 9;13:88. doi: 10.1186/1472-6963-13-88. BMC Health Serv Res. 2013. PMID: 23497271 Free PMC article.
-
Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort.Heart. 2012 Dec;98(24):1805-11. doi: 10.1136/heartjnl-2012-301992. Epub 2012 Jul 3. Heart. 2012. PMID: 22760869 Free PMC article.
-
Improved Survival for Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension: The Johns Hopkins Registry.Am J Respir Crit Care Med. 2023 Feb 1;207(3):312-322. doi: 10.1164/rccm.202204-0731OC. Am J Respir Crit Care Med. 2023. PMID: 36173815 Free PMC article.
-
Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis.J Clin Rheumatol Musculoskelet Med. 2010 Dec 1;1(2):11-20. J Clin Rheumatol Musculoskelet Med. 2010. PMID: 23626904 Free PMC article.
-
Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries.Arthritis Rheumatol. 2021 May;73(5):837-847. doi: 10.1002/art.41669. Epub 2021 Mar 29. Arthritis Rheumatol. 2021. PMID: 33538058 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical